Research programme: immunostimulant therapeutics - Volastra Therapeutics
Latest Information Update: 23 Apr 2023
At a glance
- Originator Volastra Therapeutics
- Class Antineoplastics
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 14 Apr 2023 Early research in Cancer in USA (unspecified route) (Volastra Therapeutics pipeline, April 2023)